Back

Moleculin closes MIRACLE Part A enrollment with 89 AML subjects

Verifying
  • Moleculin completed Part A enrollment in the MIRACLE trial of AnnAraC for relapsed or refractory AML.
  • 89 subjects enrolled, with one additional subject undergoing screening for Part A.
  • Moleculin expects a comprehensive Part A data readout in the first quarter of 2027.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.